Research

Hormonal

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.

ModerateSupportsMEDIUM confidence
The findings from recent clinical trials, large-scale observational studies, and real-world evidence suggest that GLP-1RAs may significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations.
Tyler Oesterle et al. · Brain Sciences · 2025

Why this rating

Evidence includes RCTs and large observational studies, but the paper highlights small sample sizes and short durations in trials.

Source

Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder

Tyler Oesterle et al. · Brain Sciences · 2025

DOI 10.3390/brainsci15070702

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →